445 related articles for article (PubMed ID: 25857609)
1. Topical cyclosporine to control ocular surface disease in patients with chronic glaucoma after long-term usage of topical ocular hypotensive medications.
Saini M; Dhiman R; Dada T; Tandon R; Vanathi M
Eye (Lond); 2015 Jun; 29(6):808-14. PubMed ID: 25857609
[TBL] [Abstract][Full Text] [Related]
2. Ocular surface evaluation in eyes with chronic glaucoma on long term topical antiglaucoma therapy.
Saini M; Vanathi M; Dada T; Agarwal T; Dhiman R; Khokhar S
Int J Ophthalmol; 2017; 10(6):931-938. PubMed ID: 28730085
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the effect of cyclosporine-A 0.05% emulsion on the ocular surface and corneal sensation following cataract surgery.
Hamada S; Moore TC; Moore JE; Al-Dreihi MG; Anbari A; Shah S
Cont Lens Anterior Eye; 2016 Feb; 39(1):15-9. PubMed ID: 26275686
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Corneal Changes Associated with Topical Antiglaucoma Therapy Using in vivo Confocal Microscopy.
Baghdasaryan E; Tepelus TC; Vickers LA; Huang P; Chopra V; Sadda SR; Lee OL
Ophthalmic Res; 2019; 61(1):51-59. PubMed ID: 29627838
[TBL] [Abstract][Full Text] [Related]
5. Increased corneal sub-basal nerve density in patients with Sjögren syndrome treated with topical cyclosporine A.
Levy O; Labbé A; Borderie V; Hamiche T; Dupas B; Laroche L; Baudouin C; Bouheraoua N
Clin Exp Ophthalmol; 2017 Jul; 45(5):455-463. PubMed ID: 27957797
[TBL] [Abstract][Full Text] [Related]
6. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology.
Martone G; Frezzotti P; Tosi GM; Traversi C; Mittica V; Malandrini A; Pichierri P; Balestrazzi A; Motolese PA; Motolese I; Motolese E
Am J Ophthalmol; 2009 Apr; 147(4):725-735.e1. PubMed ID: 19181302
[TBL] [Abstract][Full Text] [Related]
7. Topical glaucoma therapy and ocular surface disease: a prospective, controlled cohort study.
Saade CE; Lari HB; Berezina TL; Fechtner RD; Khouri AS
Can J Ophthalmol; 2015 Apr; 50(2):132-6. PubMed ID: 25863853
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of ocular surface disease in patients with glaucoma.
Mathews PM; Ramulu PY; Friedman DS; Utine CA; Akpek EK
Ophthalmology; 2013 Nov; 120(11):2241-8. PubMed ID: 23714318
[TBL] [Abstract][Full Text] [Related]
9. Tear neuromediators in eyes on chronic topical antiglaucoma therapy with and without BAK preservatives.
Murugesan V; Dwivedi R; Saini M; Gupta V; Dada T; Vivekanandhan S
Br J Ophthalmol; 2021 Jan; 105(1):141-148. PubMed ID: 31383648
[TBL] [Abstract][Full Text] [Related]
10. Ocular Surface Disease in Patients under Topical Treatment for Glaucoma.
Pérez-Bartolomé F; Martínez-de-la-Casa JM; Arriola-Villalobos P; Fernández-Pérez C; Polo V; García-Feijoó J
Eur J Ophthalmol; 2017 Nov; 27(6):694-704. PubMed ID: 28497458
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal effect of topical antiglaucoma medications on central corneal thickness.
Viswanathan D; Goldberg I; Graham SL
Clin Exp Ophthalmol; 2013; 41(4):348-54. PubMed ID: 22958109
[TBL] [Abstract][Full Text] [Related]
12. Ocular Surface Disease in Glaucoma: Effect of Polypharmacy and Preservatives.
Ramli N; Supramaniam G; Samsudin A; Juana A; Zahari M; Choo MM
Optom Vis Sci; 2015 Sep; 92(9):e222-6. PubMed ID: 25730335
[TBL] [Abstract][Full Text] [Related]
13. Effects of postoperative cyclosporine ophthalmic emulsion 0.05% (Restasis) following glaucoma surgery.
Fakhraie G; Lopes JF; Spaeth GL; Almodin J; Ichhpujani P; Moster MR
Clin Exp Ophthalmol; 2009 Dec; 37(9):842-8. PubMed ID: 20092592
[TBL] [Abstract][Full Text] [Related]
14. Prospective, Randomized, Single Masked, Parallel Study Exploring the Effects of a Preservative-Free Ophthalmic Solution Containing Hyaluronic Acid 0.4% and Taurine 0.5% on the Ocular Surface of Glaucoma Patients Under Multiple Long-Term Topical Hypotensive Therapy.
Roberti G; Agnifili L; Berardo F; Riva I; Figus M; Manni G; Quaranta L; Oddone F
Adv Ther; 2018 May; 35(5):686-696. PubMed ID: 29687335
[TBL] [Abstract][Full Text] [Related]
15. Corneal and conjunctival sensitivity in patients with dry eye: the effect of topical cyclosporine therapy.
Toker E; Asfuroğlu E
Cornea; 2010 Feb; 29(2):133-40. PubMed ID: 19966564
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications.
Fechtner RD; Godfrey DG; Budenz D; Stewart JA; Stewart WC; Jasek MC
Cornea; 2010 Jun; 29(6):618-21. PubMed ID: 20386433
[TBL] [Abstract][Full Text] [Related]
17. Clinico-cytological analysis of conjunctiva and ocular surface symptoms of patients on topical anti-glaucoma medications attending Lagos University Teaching Hospital, Lagos, Nigeria: A case-control study.
Aribaba OT; Adenekan OA; Alabi AS; Aina MT; Anunobi CC; Onakoya AO
Niger Postgrad Med J; 2023; 30(3):240-249. PubMed ID: 37675701
[TBL] [Abstract][Full Text] [Related]
18. [0.05% cyclosporine a for treatment of chronic severe ocular surface disease].
Nochez Y; Denoyer A; Pisella PJ
Can J Ophthalmol; 2009 Aug; 44(4):406-11. PubMed ID: 19606161
[TBL] [Abstract][Full Text] [Related]
19. Conjunctival and corneal sensitivity in patients under topical antiglaucoma treatment.
Romero-Díaz de León L; Morales-León JE; Ledesma-Gil J; Navas A
Int Ophthalmol; 2016 Jun; 36(3):299-303. PubMed ID: 26272426
[TBL] [Abstract][Full Text] [Related]
20. Use of Topical Cannabinomimetic Palmitoylethanolamide in Ocular Surface Disease Associated with Antiglaucoma Medications.
Di Zazzo A; Roberti G; Mashaghi A; Abud TB; Pavese D; Bonini S
J Ocul Pharmacol Ther; 2017 Nov; 33(9):670-677. PubMed ID: 29045169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
